145903-06-6

Basic information

• Product Name: 4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine
• Synonyms: JTV-519; K-201
• CAS NO: 145903-06-6
• Molecular Formula: C₂₅H₃₂N₂O₂S
• Molecular Weight: 424.60999
• Mol File: 145903-06-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine(145903-06-6)
• EPA Substance Registry System: 4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine(145903-06-6)

Safety Data

• Hazardous Substances Data: 145903-06-6(Hazardous Substances Data)

Usage

General Description

The chemical "4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine" is a compound that belongs to the benzothiazepine class of drugs. It contains a benzylpiperidine ring and a tetrahydrobenzothiazepine ring, combined with a propionyl group and a methoxy group. 4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine may have potential pharmacological effects on the central nervous system, such as being a potential calcium channel blocker or having psychoactive properties.

Upstream product

• 31252-42-3 4-benzylpyperidine 
• 865432-93-5 4-(3-bromopropionyl)-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine 

Downstream Products

• 793725-11-8 C₂₄H₃₀N₂O₂S 

Relevant articles and documents

Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.